1

Discovery

2

Optimization

3

Preclinical

4

Phase 1

Unmodified invariant Natural Killer T cells (iNKTs) – AGENT-797
Multiple Myeloma
B cell lymphoma
COVID-19
PD-1/CTLA4 Combination
Synthetic Glycolipid
Targeted invariant Natural Killer T cells (iNKTs)
Undisclosed CAR
PTT TCRs